Specifically, we found that GEN prevented BRCA1 CpG hypermethylation in ERα-positive BC cells treated with an AHR agonist as well as reversed constitutive BRCA1 CpG methylation in ERα-negative HER2-enriched cells with high levels of AHR [42]. This evidence concerns the gene BRCA1 and breast cancer.